New drug takes aim at Hard-to-Treat sarcoma
NCT ID NCT07633756
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This early-stage trial is testing a new drug called REC-617 in 15 people with a rare type of sarcoma (leiomyosarcoma) that has spread or cannot be removed and has not responded to prior treatments. The drug targets a protein (CDK7) that helps cancer cells grow. The main goal is to check the drug's safety and see if it can help control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REC-617 (a CDK7 inhibitor)
- What this could lead to
- If successful, this could point toward a new treatment option for people with a specific type of leiomyosarcoma that has not responded to other therapies.
- What could go wrong
- This is a very early, small Phase 1b trial with only 15 participants, so it is primarily testing safety. The drug may not shrink tumors or control the disease, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Blood test may spot hidden sarcoma signals
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- New pill may keep soft tissue sarcoma in check after chemo
- Dietary change explored as cancer support strategy
- Drug combo shows promise in slowing rare sarcomas